Contingency Management for Opioid and Stimulant Use Disorders in Primary Care

Last updated: October 31, 2024
Sponsor: University of Minnesota
Overall Status: Active - Recruiting

Phase

N/A

Condition

Opioid Use Disorder

Stimulant Use Disorder

Treatment

Contingency Management

Clinical Study ID

NCT05288751
FMCH-2022-30581
  • Ages > 18
  • All Genders

Study Summary

Contingency management (CM) is a behavioral intervention that involves incentivizing participants for target behaviors in a clinical setting. When applied to the treatment of substance use disorders, it has demonstrated efficacy in reducing the number of urine toxicology screens positive for illicit substances and increased engagement in treatment programs. However, there is a need to translate CM treatment to primary care settings. This study will implement and assess a CM program for patients with opioid use disorder, with or without comorbid stimulant use disorder, initiating outpatient addiction medicine services at a family medicine residency clinic. Eligible patients will earn monetary incentives for attending addiction medicine appointments and abstaining from substances during outpatient treatment. Data gathered from this pilot program will be used to improve patient outcomes, treatment, and retention for persons receiving medications for opioid use disorder (MOUDs) in a primary care setting.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • At least 18 years of age

  • Diagnosis of Opioid Use Disorder and/or Stimulant Use Disorder

  • Recently initiated medications for opioid use disorder (MOUDs) at Broadway FamilyMedicine (BFM), within 2 weeks of recruitment

  • Have an active prescription for buprenorphine-naloxone (Suboxone)

Exclusion

Exclusion Criteria:

  • Prescription for an amphetamine would exclude patients from the abstinence-based CM,but they could participate in the attendance-only CM.

  • Dementia, development disabilities, or cognitive functioning that is too low toparticipate in study measures, as determined by chart review and consultation withoverseeing physician.

Study Design

Total Participants: 42
Treatment Group(s): 1
Primary Treatment: Contingency Management
Phase:
Study Start date:
June 15, 2022
Estimated Completion Date:
May 29, 2025

Connect with a study center

  • University of Minnesota

    Minneapolis, Minnesota 55455
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.